Literature DB >> 10807787

Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome.

E Ledru1, N Christeff, O Patey, P de Truchis, J C Melchior, M L Gougeon.   

Abstract

Highly-active antiretroviral therapy (HAART) has lead to a dramatic decrease in the morbidity of patients infected with the human immunodeficiency virus (HIV). However, metabolic side effects, including lipodystrophy-associated (LD-associated) dyslipidemia, have been reported in patients treated with antiretroviral therapy. This study was designed to determine whether successful HAART was responsible for a dysregulation in the homeostasis of tumor necrosis factor-alpha (TNF-alpha), a cytokine involved in lipid metabolism. Cytokine production was assessed at the single cell level by flow cytometry after a short-term stimulation of peripheral blood T cells from HIV-infected (HIV(+)) patients who were followed during 18 months of HAART. A dramatic polarization to TNF-alpha synthesis of both CD4 and CD8 T cells was observed in all patients. Because it was previously shown that TNF-alpha synthesis by T cells was highly controlled by apoptosis, concomitant synthesis of TNF-alpha and priming for apoptosis were also analyzed. The accumulation of T cells primed for TNF-alpha synthesis is related to their escape from activation-induced apoptosis, partly due to the cosynthesis of interleukin-2 (IL-2) and TNF-alpha. Interestingly, we observed that LD is associated with a more dramatic TNF-alpha dysregulation, and positive correlations were found between the absolute number of TNF-alpha CD8 T-cell precursors and lipid parameters usually altered in LD including cholesterol, triglycerides, and the atherogenic ratio apolipoprotein B (apoB)/apoA1. Observations from the study indicate that HAART dysregulates homeostasis of TNF-alpha synthesis and suggest that this proinflammatory response induced by efficient antiretroviral therapy is a risk factor of LD development in HIV(+) patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807787

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Bone mass and mineral metabolism in HIV+ postmenopausal women.

Authors:  Michael Yin; Jay Dobkin; Karen Brudney; Carolyn Becker; Janis L Zadel; Monica Manandhar; Vicki Addesso; Elizabeth Shane
Journal:  Osteoporos Int       Date:  2005-03-08       Impact factor: 4.507

Review 2.  HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways.

Authors:  Patrick W G Mallon; Andrew Carr; David A Cooper
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

3.  HIV-associated lipodystrophy syndrome: A review of clinical aspects.

Authors:  Jean-Guy Baril; Patrice Junod; Roger Leblanc; Harold Dion; Rachel Therrien; Franãois Laplante; Julian Falutz; Pierre Côté; Marie-Nicole Hébert; Richard Lalonde; Normand Lapointe; Dominic Lévesque; Lyse Pinault; Danielle Rouleau; Cécile Tremblay; Benoãt Trottier; Sylvie Trottier; Chris Tsoukas; Karl Weiss
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-07       Impact factor: 2.471

4.  Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications.

Authors:  Sotirios Tsiodras; Christos Mantzoros
Journal:  Am J Infect Dis       Date:  2006

Review 5.  Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy.

Authors:  Bente Magny Bergersen
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Insulin resistance in HIV-related lipodystrophy.

Authors:  Nasser Mikhail
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

7.  Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

Authors:  P Tebas; J Zhang; R Hafner; K Tashima; A Shevitz; K Yarasheski; B Berzins; S Owens; J Forand; S Evans; R Murphy
Journal:  J Antimicrob Chemother       Date:  2009-03-19       Impact factor: 5.790

8.  Genetic analysis implicates resistin in HIV lipodystrophy.

Authors:  Koustubh Ranade; William J Geese; Mustafa Noor; Oliver Flint; Pablo Tebas; Kathleen Mulligan; William Powderly; Steven K Grinspoon; Michael P Dube
Journal:  AIDS       Date:  2008-08-20       Impact factor: 4.177

9.  Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients.

Authors:  B Lindegaard; P Keller; H Bruunsgaard; J Gerstoft; B K Pedersen
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

10.  Human immunodeficiency virus genotype and hypertriglyceridemia.

Authors:  Soni J Anderson; John F Bradley; Andrea Ferreira-Gonzalez; Carleton T Garrett
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.